Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01923389 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01923389 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 4 participants.
The verdict
NCT01923389, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
Interventions
- OTHER Placebo
- DRUG 100 mg PF-05231023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01923389
The ClinicalTrials.gov registry entry for NCT01923389 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01923389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01923389 about?
NCT01923389 is a clinical study titled "Multiple Dose Study Of PF-05231023 In Obese Adult Subjects". This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
What is the current status of trial NCT01923389?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2013-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01923389?
The interventions under investigation include: Placebo (OTHER), 100 mg PF-05231023 (DRUG).
Who is sponsoring clinical trial NCT01923389?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.